Protalix BioTherapeutics (PLX) Earnings Date, Estimates & Call Transcripts

$1.15
-0.03 (-2.54%)
(As of 04/26/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Mar. 14)
-$0.07 Missed By -$0.04
Consensus EPS
(Mar. 14)
-$0.03
Skip Charts & View Estimated and Actual Earnings Data

PLX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PLX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Protalix BioTherapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate:$0.14 EPS
Next Year EPS Consensus Estimate: $0.81 EPS

PLX Earnings Date and Information

Protalix BioTherapeutics last posted its earnings data on March 14th, 2024. The reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.04. The company earned $10.49 million during the quarter, compared to analyst estimates of $8.15 million. Protalix BioTherapeutics has generated $0.05 earnings per share over the last year ($0.05 diluted earnings per share) and currently has a price-to-earnings ratio of 23.0. Earnings for Protalix BioTherapeutics are expected to grow by 478.57% in the coming year, from $0.14 to $0.81 per share. Protalix BioTherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Protalix BioTherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)
------- 
3/14/2024Q4 2023($0.03)($0.07)($0.04)($0.07)$8.15 million$10.49 million    
11/6/2023Q3 2023($0.07)($0.04)+$0.03($0.04)$7.64 million$10.35 million    
8/7/2023Q2 2023($0.04)$0.21+$0.25$0.21$10.22 million$35.08 million
8/7/2023Q2 2023($0.04)$0.21+$0.25$0.21$10.22 million$35.08 million    
5/4/2023Q1 2023-($0.05)($0.05)($0.05)-$9.59 million
5/4/2023Q1 2023-($0.05)($0.05)($0.05)-$9.59 million
2/27/2023Q4 2022($0.15)($0.07)+$0.08($0.07)$6.12 million$8.62 million
2/27/2023Q4 2022($0.15)($0.07)+$0.08($0.07)$6.12 million$8.62 million
2/27/2023Q4 2022($0.15)($0.07)+$0.08($0.07)$6.12 million$8.62 million
11/14/2022Q3 2022($0.15)($0.07)+$0.08($0.07)$5.69 million$14.18 million
11/14/2022Q3 2022($0.15)($0.07)+$0.08($0.07)$5.69 million$14.18 million
11/14/2022Q3 2022($0.15)($0.07)+$0.08($0.07)$5.69 million$14.18 million
8/15/2022Q2 2022($0.18)($0.11)+$0.07($0.11)$2.68 million$8.75 million
8/15/2022Q2 2022($0.18)($0.11)+$0.07($0.11)$2.68 million$8.75 million
8/15/2022Q2 2022($0.18)($0.11)+$0.07($0.11)$2.68 million$8.75 million    
5/16/2022Q1 2022-($0.05)($0.05)($0.05)-$16.09 million
5/16/2022Q1 2022-($0.05)($0.05)($0.05)-$16.09 million
5/16/2022Q1 2022-($0.05)($0.05)($0.05)-$16.09 million
3/31/2022Q4 2021($0.11)($0.14)($0.03)($0.14)$7.79 million$8.55 million
3/31/2022Q4 2021($0.11)($0.14)($0.03)($0.14)$7.79 million$8.55 million
3/31/2022Q4 2021($0.11)($0.14)($0.03)($0.14)$7.79 million$8.55 million
11/15/2021Q3 2021($0.12)($0.09)+$0.03($0.09)$6.90 million$12.05 million
11/15/2021Q3 2021($0.12)($0.09)+$0.03($0.09)$6.90 million$12.05 million
11/15/2021Q3 2021($0.12)($0.09)+$0.03($0.09)$6.90 million$12.05 million    
8/16/2021Q2 2021($0.08)($0.25)($0.17)($0.25)$8.30 million$6.43 million
8/16/2021Q2 2021($0.08)($0.25)($0.17)($0.25)$8.30 million$6.43 million
8/15/2021Q2($0.08)($0.25)($0.17)($0.25)$8.30 million$6.43 million  
5/14/2021Q1 2021($0.17)($0.14)+$0.03($0.14)$10.95 million$11.32 million
5/14/2021Q1 2021($0.17)($0.14)+$0.03($0.14)$10.95 million$11.32 million
5/13/2021Q1 2021($0.17)($0.14)+$0.03($0.14)$10.95 million$11.32 million  

Protalix BioTherapeutics Earnings - Frequently Asked Questions

When is Protalix BioTherapeutics's earnings date?

Protalix BioTherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on PLX's earnings history.

Did Protalix BioTherapeutics beat their earnings estimates last quarter?

In the previous quarter, Protalix BioTherapeutics (NYSE:PLX) missed the analysts' consensus estimate of ($0.03) by $0.04 with a reported earnings per share (EPS) of ($0.07). Learn more on analysts' earnings estimate vs. PLX's actual earnings.

How can I listen to Protalix BioTherapeutics's earnings conference call?

The conference call for Protalix BioTherapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Protalix BioTherapeutics's conference call transcript?

The conference call transcript for Protalix BioTherapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Protalix BioTherapeutics generate each year?

Protalix BioTherapeutics (NYSE:PLX) has a recorded annual revenue of $65.49 million.

How much profit does Protalix BioTherapeutics generate each year?

Protalix BioTherapeutics (NYSE:PLX) has a recorded net income of $8.31 million. PLX has generated $0.05 earnings per share over the last four quarters.

What is Protalix BioTherapeutics's price-to-earnings ratio?

Protalix BioTherapeutics (NYSE:PLX) has a trailing price-to-earnings ratio of 23.00 and a forward price-to-earnings ratio of 8.21.

What is Protalix BioTherapeutics's EPS forecast for next year?

Protalix BioTherapeutics's earnings are expected to grow from $0.14 per share to $0.81 per share in the next year, which is a 478.57% increase.


More Earnings Resources from MarketBeat

This page (NYSE:PLX) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners